Skip to content

Prognostic Value of Plasma ctDNA mutation patterns in Stage III Colon Cancer

Prognostic Value of Plasma ctDNA mutation patterns in Stage III Colon Cancer

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800018754
Enrollment
Unknown
Registered
2018-10-08
Start date
2018-08-01
Completion date
Unknown
Last updated
2018-10-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colon Cancer

Interventions

Gold Standard:Clinical outcome

Sponsors

Fudan University Shanghai Cancer Center
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1) Aged =18 years; 2) Patients should have colon cancer, whose tumor located at least 12cm from anal verge; 3) Patients with colon cancers undergo radical resection at Fudan University Shanghai Cancer Center (FUSCC); 4) Confirmed adenocarcinoma with AJCC stage III colon cancer by postoperative pathological assessment; 5) Patients should be assessed to be able to receive standard adjuvant chemotherapy for at least 3 months; 6) Patient written informed consent; 7) Plasma samples with =4ml available.

Exclusion criteria

Exclusion criteria: 1) Patients with rectal cancers, whose tumors locate within 12cm from anal verge; 2) Patients who have received neoadjuvant chemotherapy or radiotherapy; 3) Patients who need adjuvant radiotherapy; 4) Patients who are intolerable to have adjuvant chemotherapy for at least 3 months; 5) Patients without surgical tissue samples.

Design outcomes

Primary

MeasureTime frame
RFS;SPE, SEN, ACC, ROC;

Countries

China

Contacts

Public ContactJunjie Peng

Fudan University Shanghai Cancer Center

pengjj67@hotmail.com+86 18017317122

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 19, 2026